UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000626
Receipt number R000000756
Scientific Title Prognostic Value of Cardiac 123I-Metaiodobenzylguanidine Imaging in Patients With Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction
Date of disclosure of the study information 2007/03/03
Last modified on 2007/03/01 15:41:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prognostic Value of Cardiac 123I-Metaiodobenzylguanidine Imaging in Patients With Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction

Acronym

Prognostic Value of 123I-MIBG in CHF

Scientific Title

Prognostic Value of Cardiac 123I-Metaiodobenzylguanidine Imaging in Patients With Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction

Scientific Title:Acronym

Prognostic Value of 123I-MIBG in CHF

Region

Japan


Condition

Condition

chronic heart failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigated the usefulness of 123I-metaiodobenzylguanidine (MIBG) scintigraphy in the evaluation of long-term prognosis in stabilized patients with chronic heart failure.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

Fatal cardiac events during the study.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Definitive signs and symptoms of decompensated acute heart failure and required hospitalization
2)Left ventricular ejection fraction (LVEF) of less than 45%
3)No cardiac events for at least 5 months after hospital discharge
4)Fully informed consent was obtained

Key exclusion criteria

1)Congenital heart disease
2)Unstable angina
3)Acute myocardial infarction
4)Hepatic failure
5)Renal failure
6)Active cancer
7)Severe heart failure requiring mechanical support (intraaortic balloon pumping, left ventricular assist device, or cardiac resynchronization therapy)
8)Requiring heart transplantation

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuichi Ichikawa

Organization

Kitakanto Cardiovascular Hospital

Division name

Internal Medicine

Zip code


Address

740 Shimohakoda, Hokkitsu-machi, Shibukawa, Gunma, Japan

TEL

027-232-7111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Shu Kasama

Organization

Kitakanto Cardiovascular Hospital

Division name

Internal Medicine

Zip code


Address

740 Shimohakoda, Hokkitsu-machi, Shibukawa, Gunma, Japan

TEL

027-232-7111

Homepage URL


Email

s-kasama@bay.wind.ne.jp


Sponsor or person

Institute

Kitakanto Cardiovascular Hospital

Institute

Department

Personal name



Funding Source

Organization

Kitakanto Cardiovascular Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2007 Year 03 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

1999 Year 11 Month 10 Day

Date of IRB


Anticipated trial start date

1999 Year 12 Month 01 Day

Last follow-up date

2006 Year 11 Month 01 Day

Date of closure to data entry

2007 Year 03 Month 01 Day

Date trial data considered complete

2007 Year 03 Month 01 Day

Date analysis concluded

2007 Year 03 Month 01 Day


Other

Other related information

Influence of MIBG scintigraphic parameters on cumulative survival, prospective study


Management information

Registered date

2007 Year 03 Month 01 Day

Last modified on

2007 Year 03 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000756


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name